John is a health content expert and wellness researcher with a passion for preventative medicine and holistic lifestyle habits. Known for his ability to make intricate health topics easy to digest, John focuses on providing scientifically grounded insights that help readers take control of their long-term well-being. When he isn't researching the latest in clinical wellness, he is exploring the intersection of technology and human performance.
A new AI-driven screening tool is accelerating Alzheimer's clinical trial recruitment by accurately identifying eligible patients through EHR analysis.
CSPC Pharmaceutical secures NMPA approval for Goserelin sustained-release injection trials, aiming to advance hormone-sensitive cancer treatment in China.
New proteomic aging clocks are redefining Phase 2a trial success. Learn how measuring biological age is becoming a standard for future clinical validation.
Nektar is set to release 24-week durability data for rezpegaldesleukin in alopecia areata. Discover how this IL-2 agonist impacts long-term hair regrowth.
BridgeBio Pharma is pivoting its BBO-8520 drug candidate toward combination therapies for second-line NSCLC to improve outcomes in KRAS-mutant lung cancer.
Novartis reports a significant setback as their new heart drug fails to meet primary endpoints in Phase 3 trials. Read the full analysis on this development.
Dr. Sumanta K. Pal identifies a critical gap in bladder cancer trial access, urging for more inclusive and decentralized research to improve patient care.